Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study backs T-wave alternans test:

This article was originally published in Clinica

Executive Summary

Measuring T-wave alternans, subtle beat-to-beat fluctuations in heartbeat, could help predict ventricular tachycardia (VT) in patients with non-ischaemic dilated cardiomyopathy (DCM), according to a study published in the Journal of the American College of Cardiology (August). The sensitivity, specificity and predictive accuracy of T-wave alternans for VT in 58 patients with DCM were 88%, 72% and 77% respectively. US company Cambridge Heart of Bedford, Massachusetts, which makes the only non-invasive T-wave alternans test with FDA clearance, said the findings were significant since a conventional electrophysiology study is not considered useful in diagnosing patients with non-ischaemic DCM.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079322

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel